The pharmaceutical industry is an industry that provides medicines related to the health and life of the people. The pharmaceutical industry is a traditional regulation industry with the characteristics of R&D(Research and Development), purchasing, manufacturing, distribution and consumption under strict government management. Until now, pharmaceutical companies have continued to make efforts to maintain competitiveness through patent management, new product development, and marketing. However, industries are rapidly changing, including rising costs for developing new products and expanding generic markets. As these changes and uncertainties in the management environment increase, efforts are required to improve the competitiveness of the pharmaceutical industry from a new perspective. In this study, we intend to examine the impact of SCM(Supply Chain Management) dynamic capability of pharmaceutical companies on corporate performance through partnerships to respond to market changes and uncertainties. It was determined that the agility, visibility and flexibility that constitutes the SCM dynamic capabilities would affect the performance of pharmaceutical companies. In this study, the importance of SCM dynamic capabilities and cooperative relationships was identified through surveys by SCM managers of pharmaceutical companies. Consequently, in the pharmaceutical industry, which is a regulatory industry, we have identified that SCM dynamic capabilities and cooperative relationships with partner companies have a significant impact on corporate performance.

The present study identified several antecedents that create perceived resistance to supply chain management (SCM) change. This work particularly emphasizes SCM change, which is notable given its central role in reacting market orientation and varied environmental and managerial conditions. A careful case study on a small and medium sized food production company in South Korea leads to the formulation of our framework including one second-order construct of ‘resistance’ as well as eight first-order constructs of ‘implementing the payment terms’, ‘balancing of business process’, ‘fear of responsibility’, ‘business sustainability transparency’, ‘past experience of failure’, ‘competence of work personnel’, ‘cooperation with third parties’ and ‘sharing personnel information with partner’. The hypothesized relation of first- and second-order construct was validated using survey sample data collected from 350 respondents who completed their questionnaire instrument. Results from confirmatory factor analysis revealed that nomological validity was established at statistical significance level by identifying six first order constructs of ‘implementing the payment terms’, ‘fear of responsibility’, ‘business sustainability transparency’, ‘past experience of failure’, a conbined construct of 'competence of work personnel/ cooperation with third parties’ and ‘sharing personnel information with partner’. The findings from our work are expected to provide important insights to the strategy for SCM risk management for small and medium sized company.